To enable those with hearing loss to live a life without limits, and hear a world of sound. Hemideina takes inspiration from nature to develop solutions for human hearing. It is our mission to be a trusted source of innovation for those with hearing loss.
Dr Liz Williams
co-founder, director & chief executive officer
Liz has experience in commercialisation and the lean startup methodology. Having mentored early stage start-ups through customer validation and product-market fit, Liz brings this understanding to Hemideina.
Liz has a PhD in Chemistry from the University of Cambridge, and was awarded the BioMelbourne Network Emerging Woman in Leadership Award, 2018.
Dr Kate Lomas
co-founder, director & Chief Scientific Officer
Kate is the inventor of the Hemideina technology, having taken inspiration from the insect world. Kate holds a PhD in biophysics from Auckland University, and is one of only a handful of experts in the field, worldwide.
Kate was a finalist for the New Zealand PM’s Prize for Emerging Scientist of the Year, and a finalist for the L’Oreal Women in Science Fellowship.
chairman of the board
Andrew brings a wealth of experience in the med tech sector, taking products from ideation to market. He is the former CEO of Global Kinetics, a Parkinson’s wrist watch medical device used for monitoring and disease management. Andrew is currently Director of the BioMelbourne Network, Non-Executive Director of TMS Clinics Australia and Chairman at Agersens. Andrew was the former CEO of ESCOR Private Equity (a Smorgon Family Company).
Andrew is managing director of Chatsworth Associates, which provides advice in capital raising and commercial strategy.
Dr. Anna Lavelle
INDEPENDENT BOARD DIRECTOR
Dr Lavelle provides over 25 years’ experience in healthcare delivery, technology development and industry policy for not-for-profit, for profit and government entities. Anna was recently awarded the Johnson and Johnson/AusBiotech “Industry Leader of the Year” and is recognised as one of the global top 100 “World Visionaries” in biotechnology. She provides experience in governance and health policy.
Mr. Jonathan Tooth
SERIES A REPRESENTATIVE BOARD MEMBER
Mr Tooth is currently Director, Corporate at Henslow, an independent advisory firm that supports growing companies and their stakeholders through every phase of the business evolutionary cycle. He has significant expertise and experience in capital raisings, IPOs, corporate advice and financial transactions. Jonathan is also a Non-Executive Director of several ASX listed companies, such as Vita Life Sciences.